Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Sell
47
LXRX Quote, Financials, Valuation and Earnings
Last price:
$0.75
Seasonality move
:
5.3%
Day range:
$0.71 - $0.76
52-week range:
$0.28 - $2.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.39x
P/B ratio:
2.21x
Volume:
4.3M
Avg. volume:
4M
1-year change:
-57.14%
Market cap:
$272.4M
Revenue:
$31.1M
EPS (TTM):
-$0.51
Analysts' Opinion
-
Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.58, Lexicon Pharmaceuticals has an estimated upside of 244% from its current price of $0.75.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $0.70 representing 100% downside risk from its current price of $0.75.
Fair Value
-
According to the consensus of 3 analysts, Lexicon Pharmaceuticals has 244% upside to fair value with a price target of $2.58 per share.
LXRX vs. S&P 500
-
Over the past 5 trading days, Lexicon Pharmaceuticals has overperformed the S&P 500 by 7.95% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Lexicon Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lexicon Pharmaceuticals has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Lexicon Pharmaceuticals reported revenues of $1.3M.
Earnings Growth
-
Lexicon Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Lexicon Pharmaceuticals reported earnings per share of -$0.07.
Enterprise value:
178.2M
EV / Invested capital:
--
Price / LTM sales:
8.39x
EV / EBIT:
--
EV / Revenue:
5.71x
PEG ratio (5yr expected):
-0.15x
EV / Free cash flow:
-1.06x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$30.6M
Return On Assets:
-51.91%
Net Income Margin (TTM):
-568.04%
Return On Equity:
-90.8%
Return On Invested Capital:
-60.04%
Operating Margin:
-2034.79%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $126K | $2.3M | $31.2M | $1.1M | $1.3M | |
| Gross Profit | $126K | $2.2M | $30.6M | $1.1M | $1.2M | |
| Operating Income | -$108.5M | -$185.9M | -$177.5M | -$45.3M | -$25.7M | |
| EBITDA | -$105.5M | -$176.8M | -$164.3M | -$43.3M | -$23.3M | |
| Diluted EPS | -$0.62 | -$0.83 | -$0.51 | -$0.20 | -$0.07 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $145.4M | $88.4M | $109.5M | $364.6M | $245.8M | |
| Total Assets | $193.3M | $136.2M | $162.7M | $417.2M | $297.7M | |
| Current Liabilities | $39M | $18.9M | $20.4M | $23.4M | $110.7M | |
| Total Liabilities | $40.7M | $43.5M | $74.7M | $128.4M | $174.6M | |
| Total Equity | $152.5M | $92.7M | $88M | $288.9M | $123M | |
| Total Debt | $11.7M | $23.5M | $48.8M | $99.9M | $100.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$97M | -$185.4M | -$167.4M | -$55.1M | -$43.8M | |
| Cash From Investing | -$54.6M | -$172.3M | $135.4M | -$110.2M | $40.6M | |
| Cash From Financing | $118.1M | $428.2M | -$1.6M | $239.4M | -$572K | |
| Free Cash Flow | -$98.5M | -$185.6M | -$167.4M | -$55.1M | -$43.8M | |
LXRX
Sector
Market Cap
$272.4M
$32.8M
Price % of 52-Week High
30.61%
46.34%
Dividend Yield
0%
0%
Shareholder Yield
0.94%
-0.74%
1-Year Price Total Return
-57.14%
-35.67%
Beta (5-Year)
1.003
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.71
200-day SMA
Sell
Level
$0.92
Bollinger Bands (100)
Buy
Level
0.45 - 0.75
Chaikin Money Flow
Sell
Level
-401M
20-day SMA
Buy
Level
$0.69
Relative Strength Index (RSI14)
Buy
Level
61.19
ADX Line
Buy
Level
21.2
Williams %R
Neutral
Level
-24.7072
50-day SMA
Buy
Level
$0.64
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
829.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.3102)
Sell
CA Score
(Annual)
Level (-3.7928)
Sell
Beneish M-Score
(Annual)
Level (18.607)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (4.4102)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Stock Forecast FAQ
In the current month, LXRX has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The LXRX average analyst price target in the past 3 months is $2.58.
-
Where Will Lexicon Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lexicon Pharmaceuticals share price will rise to $2.58 per share over the next 12 months.
-
What Do Analysts Say About Lexicon Pharmaceuticals?
Analysts are divided on their view about Lexicon Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lexicon Pharmaceuticals is a Sell and believe this share price will drop from its current level to $0.70.
-
What Is Lexicon Pharmaceuticals's Price Target?
The price target for Lexicon Pharmaceuticals over the next 1-year time period is forecast to be $2.58 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is LXRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lexicon Pharmaceuticals is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of LXRX?
You can purchase shares of Lexicon Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lexicon Pharmaceuticals shares.
-
What Is The Lexicon Pharmaceuticals Share Price Today?
Lexicon Pharmaceuticals was last trading at $0.75 per share. This represents the most recent stock quote for Lexicon Pharmaceuticals. Yesterday, Lexicon Pharmaceuticals closed at $0.75 per share.
-
How To Buy Lexicon Pharmaceuticals Stock Online?
In order to purchase Lexicon Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
How High Will Take-Two Stock Go?
Take-Two Interactive (NASDAQ:TTWO) is the video game development company behind…
Stock Ideas
Buy
64
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
37
RGC alert for Jun 21
Regencell Bioscience Holdings [RGC] is down 40.02% over the past day.
Buy
83
GMS alert for Jun 21
GMS [GMS] is up 23.79% over the past day.
Buy
57
QNTM alert for Jun 21
Quantum BioPharma [QNTM] is up 13.82% over the past day.
